| Nov 12 |
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
|
| Nov 6 |
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
|
| Oct 15 |
Ocular Therapeutix announces accelerated timelines for trial of AXPAXLI in wet AMD
|
| Oct 15 |
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
|
| Oct 14 |
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
|
| Oct 11 |
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
|
| Oct 9 |
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
|
| Oct 8 |
Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength
|
| Sep 5 |
Ocular Therapeutix™ to Present at September Retina Meetings
|
| Sep 4 |
Ocular Therapeutix™ to Present at Two Investor Conferences in September
|
